Histamine H3 receptor antagonists go to clinics.

Within the recent years novel lead optimisations for histamine H(3) receptor antagonists made their way from bench to bedside. Structure-activity relationships, cross-affinities and side effects as well as pharmacokinetic profiling will be discussed on selected promising compound series. Due to diversity in potential therapeutic applications and in some cases a controversial debate, different indications will be highlighted with the potential and the problems of the test compounds, e.g. sleep-wake disorders, attention-deficient hyperactivity disorder, epilepsy, cognitive impairment, schizophrenia, obesity and neuropathic pain. First data published on clinical trials phase II (IIb) are presented showing proof of concept of H(3) receptor antagonists in narcolepsy and photo-induced epilepsy.

[1]  H. Haas,et al.  GABAB‐receptor‐mediated control of GABAergic inhibition in rat histaminergic neurons in vitro , 1999, The European journal of neuroscience.

[2]  J. Schwartz,et al.  Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. , 2008, Bioorganic & medicinal chemistry.

[3]  S. Cragg,et al.  Histamine H3 Receptors Inhibit Serotonin Release in Substantia Nigra Pars Reticulata , 2004, The Journal of Neuroscience.

[4]  H. Yamasue,et al.  Neuroanatomy and neurophysiology in schizophrenia , 2002, Neuroscience Research.

[5]  L. Tuomisto,et al.  Is histamine an anticonvulsive inhibitory transmitter? , 1986, Neuropharmacology.

[6]  K. Browman,et al.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders , 2008, British journal of pharmacology.

[7]  J. Schwartz,et al.  [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor. , 1996, Journal of medicinal chemistry.

[8]  I. D. Esch,et al.  Constitutive activity of H3 autoreceptors modulates histamine synthesis in rat brain through the cAMP/PKA pathway , 2006, Neuropharmacology.

[9]  F. Sánchez-Jiménez,et al.  The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. , 2008, Cancer biology & therapy.

[10]  U. Schaefer,et al.  Histamine H3-receptor signaling in cardiac sympathetic nerves: Identification of a novel MAPK-PLA2-COX-PGE2-EP3R pathway. , 2007, Biochemical pharmacology.

[11]  Genomic organization and characterization of splice variants of the human histamine H3 receptor. , 2001 .

[12]  H. Yoshimatsu,et al.  Neuronal histamine and its receptors in obesity and diabetes. , 2007, Current diabetes reviews.

[13]  Bengt Winblad,et al.  Akt activity in Alzheimer's disease and other neurodegenerative disorders , 2004, Neuroreport.

[14]  C. Dvorak,et al.  Recent medicinal chemistry of the histamine H3 receptor. , 2006, Progress in medicinal chemistry.

[15]  A. Hancock.  The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. , 2006, Biochemical pharmacology.

[16]  Synthesis and biological evaluation of diamine-based histamine H3 antagonists with serotonin reuptake inhibitor activity. , 2007, Bioorganic & medicinal chemistry letters.

[17]  D. Weiner,et al.  Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor , 2002, Neuropharmacology.

[18]  M. Dutia,et al.  Histaminergic and glycinergic modulation of GABA release in the vestibular nuclei of normal and labyrinthectomised rats , 2006, The Journal of physiology.

[19]  J. Schwartz,et al.  Highly potent and selective ligands for histamine H3-receptors , 1987, Nature.

[20]  H. Stark,et al.  Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats , 1998, Brain Research.

[21]  J. Schwartz,et al.  Novel Histamine H3‐Receptor Antagonists with Benzyl Ether Structure or Related Moieties: Synthesis and Structure‐Activity Relationships , 1996, Archiv der Pharmazie.

[22]  H. Stark,et al.  Medicinal chemistry of histamine H3 receptor agonists , 1998 .

[23]  J. Arias-Montaño.  Histamine H3 receptors and their role in basal ganglia physiology and pathophysiology , 2007 .

[24]  P. Bonaventure,et al.  Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[25]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[26]  L. Horrocks,et al.  Phospholipase A₂-Generated Lipid Mediators in the Brain: The Good, the Bad, and the Ugly , 2006 .

[27]  J. Schwartz,et al.  Azines and Diazines as Potential Histamine H3‐Receptor Antagonists , 1995, Archiv der Pharmazie.

[28]  H. Haas,et al.  The mechanism of spontaneous firing in histamine neurons , 2001, Behavioural Brain Research.

[29]  Sayaka Ito,et al.  Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists. , 2008, Bioorganic & Medicinal Chemistry Letters.

[30]  Y. Fujii,et al.  The effects of histamine H3-receptor antagonists on amygdaloid kindled seizures in rats , 1998, Brain Research Bulletin.

[31]  S. Pal,et al.  Thioperamide, a selective histamine H3 receptor antagonist, protects against PTZ-induced seizures in mice. , 2000, Life sciences.

[32]  C. Kaufmann,et al.  Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms , 1995, Schizophrenia Research.

[33]  A. Hancock,et al.  A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans. , 2004, Bioorganic & medicinal chemistry letters.

[34]  J. Schwartz,et al.  An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin−/− mice and patients , 2008, Neurobiology of Disease.

[35]  S. Pal,et al.  Histamine and selective H3-receptor ligands: a possible role in the mechanism and management of epilepsy , 2001, Pharmacology Biochemistry and Behavior.

[36]  K. Browman,et al.  The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. , 2008, Journal of medicinal chemistry.

[37]  A. C. Reid,et al.  Histamine H3-Receptor-Induced Attenuation of Norepinephrine Exocytosis: A Decreased Protein Kinase A Activity Mediates a Reduction in Intracellular Calcium , 2005, Journal of Pharmacology and Experimental Therapeutics.

[38]  J. Féger,et al.  Histaminergic pathway in rat brain evidenced by lesions of the medial forebrain bundle. , 1974, Science.

[39]  J. Schwartz,et al.  Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade. , 1999, The Journal of pharmacology and experimental therapeutics.

[40]  T. Lovenberg,et al.  Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. , 2008, Bioorganic & medicinal chemistry.

[41]  T. Watanabe,et al.  Effect of thioperamide, a histamine H3 receptor antagonist, on electrically induced convulsions in mice. , 1993, European journal of pharmacology.

[42]  J. Schwartz,et al.  Diphenylmethyl ethers: synthesis and histamine H3-receptor antagonist in vitro and in vivo activity , 1996 .

[43]  R. Leurs,et al.  The Akt/GSK‐3β axis as a new signaling pathway of the histamine H3 receptor , 2007 .

[44]  H. Haas,et al.  Histamine in the nervous system. , 2008, Physiological reviews.

[45]  J. J. Stephanos.  Drug-protein interactions: two-site binding of heterocyclic ligands to a monomeric hemoglobin. , 1996, Journal of inorganic biochemistry.

[46]  M. Treviño,et al.  Pre-synaptic histamine H3 receptors regulate glutamate, but not GABA release in rat thalamus , 2007, Neuropharmacology.

[47]  J. Seamans,et al.  Dopamine and Serotonin Interactions in the Prefrontal Cortex: Insights on Antipsychotic Drugs and Their Mechanism of Action , 2007, Pharmacopsychiatry.

[48]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[49]  J. Schwartz,et al.  Protean agonism at histamine H3 receptors in vitro and in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Henry,et al.  An efficient multigram synthesis of the potent histamine H3 antagonist GT-2331 and the reassessment of the absolute configuration. , 2004, The Journal of organic chemistry.

[51]  L Landais,et al.  BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[52]  J. Schwartz,et al.  Novel partial agonists for the histamine H(3) receptor with high in vitro and in vivo activity. , 1999, Journal of medicinal chemistry.

[53]  C. Tanaka,et al.  Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia , 1991, Biological Psychiatry.

[54]  J. Siegel,et al.  Activity of dorsal raphe cells across the sleep–waking cycle and during cataplexy in narcoleptic dogs , 2004, The Journal of physiology.

[55]  K. Rimvall,et al.  Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides. , 2006, Bioorganic & medicinal chemistry letters.

[56]  K. Fink,et al.  Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[57]  M. Erlander,et al.  Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles. , 2000, The Journal of pharmacology and experimental therapeutics.

[58]  M. Decker.  Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. , 2007, Mini reviews in medicinal chemistry.

[59]  J. Schwartz,et al.  Development of FUB 181, a Selective Histamine H3‐Receptor Antagonist of High Oral in Vivo Potency with 4‐(?gv‐(Arylalkyloxy)alkyl)‐1H‐imidazole Structure , 1998, Archiv der Pharmazie.

[60]  C. Kamei,et al.  Histaminergic mechanisms in amygdaloid-kindled seizures in rats , 1998, Epilepsy Research.

[61]  J. Schwartz,et al.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.

[62]  R. Rodriguiz,et al.  Role of GSK3β in behavioral abnormalities induced by serotonin deficiency , 2008, Proceedings of the National Academy of Sciences.

[63]  C R Ganellin,et al.  Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain , 2000, British journal of pharmacology.

[64]  R. Huganir,et al.  MAPK cascade signalling and synaptic plasticity , 2004, Nature Reviews Neuroscience.

[65]  A. Hancock,et al.  Fluorescent benzofuran histamine H3 receptor antagonists with sub-nanomolar potency , 2006, Inflammation Research.

[66]  D. Farzin,et al.  Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists , 2002, Pharmacology Biochemistry and Behavior.

[67]  K. Browman,et al.  Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. , 2007, Biochemical pharmacology.

[68]  A. Kjaer,et al.  Increased Susceptibility to Diet-Induced Obesity in Histamine-Deficient Mice , 2006, Neuroendocrinology.

[69]  L. Goodman,et al.  Comparative assays of antiepileptic drugs in mice and rats. , 1952, The Journal of pharmacology and experimental therapeutics.

[70]  J. Schwartz,et al.  Ciproxifan, a histamine H3‐receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum , 2003, The European journal of neuroscience.

[71]  M. Williams,et al.  Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. , 2004, Biochemical pharmacology.

[72]  E. Bush,et al.  In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. , 2004, Basic & clinical pharmacology & toxicology.

[73]  C. Economo.  SLEEP AS A PROBLEM OF LOCALIZATION , 1930 .

[74]  J. Schwartz,et al.  Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[75]  H. Kotani,et al.  Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. , 2006, Journal of pharmacological sciences.

[76]  J. Schwartz,et al.  Different antagonist binding properties of human and rat histamine H3 receptors. , 2001, Bioorganic & medicinal chemistry letters.

[77]  P. Panula,et al.  Histamine-containing neurons in the rat hypothalamus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[78]  M. Letavic,et al.  Histamine H3 antagonists as wake-promoting and pro-cognitive agents. , 2008, Current topics in medicinal chemistry.

[79]  R. Leurs,et al.  The histamine H3 receptor: from gene cloning to H3 receptor drugs , 2005, Nature Reviews Drug Discovery.

[80]  R. Leurs,et al.  Histamine H3 receptor ligands break ground in a remarkable plethora of therapeutic areas , 2007, Expert opinion on investigational drugs.

[81]  Takehiko Watanabe,et al.  Proconvulsive effects of histamine H1-antagonists on electrically-induced seizure in developing mice , 2005, Psychopharmacology.

[82]  P. Bonaventure,et al.  Histamine H3 receptor antagonists: from target identification to drug leads. , 2007, Biochemical pharmacology.

[83]  K. Browman,et al.  Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan , 2004, Behavioural Brain Research.

[84]  Michael H. Abraham,et al.  Physicochemical analysis of the factors governing distribution of solutes between blood and brain , 1994 .

[85]  J. Arrang,et al.  Histamine H3 and dopamine D2 receptor-mediated [35S]GTPgamma[S] binding in rat striatum: evidence for additive effects but lack of interactions. , 2007, Biochemical pharmacology.

[86]  M. Malone.  Medications Associated with Weight Gain , 2005, The Annals of pharmacotherapy.

[87]  K. Fink,et al.  Involvement of presynaptic H3 receptors in the inhibitory effect of histamine on serotonin release in the rat brain cortex , 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

[88]  N. Okamura,et al.  Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors , 2007, Neuroscience Research.

[89]  J. Siegel,et al.  Locus coeruleus neurons: cessation of activity during cataplexy , 1999, Neuroscience.

[90]  J. Schwartz,et al.  Piperidino-hydrocarbon compounds as novel non-imidazole histamine H(3)-receptor antagonists. , 2002, Bioorganic & medicinal chemistry.

[91]  T. Lovenberg,et al.  Coupling of histamine H3 receptors to neuronal Na+/H+ exchange: A novel protective mechanism in myocardial ischemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[92]  J. Schwartz,et al.  Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. , 2007, Biochemical pharmacology.

[93]  T. Lovenberg,et al.  Aplysamine-1 and related analogs as histamine H3 receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[94]  K. Leuner,et al.  Dopamine in the Prefrontal Cortex and its Different Modulation by Conventional and Atypical Antipsychotics , 2007 .

[95]  Ming-Fung Wu,et al.  Cataplexy-Active Neurons in the Hypothalamus Implications for the Role of Histamine in Sleep and Waking Behavior , 2004, Neuron.

[96]  D. Macneil,et al.  Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor. , 2006, European journal of pharmacology.

[97]  R. Capon,et al.  2 New Bromotyrosine-Derived Metabolites From An Australian Marine Sponge, Aplysina Sp , 1989 .

[98]  P. Bonaventure,et al.  Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. , 2007, European journal of pharmacology.

[99]  Craig W Berridge,et al.  4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists. , 2005, Journal of medicinal chemistry.

[100]  T. Kenakin.  Principles: receptor theory in pharmacology. , 2004, Trends in pharmacological sciences.

[101]  Michael A. Briggs,et al.  Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. , 2007, Biochemical pharmacology.

[102]  Christopher Browning,et al.  4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists. , 2007, Journal of medicinal chemistry.

[103]  Ramón Cacabelos,et al.  Histamine function in brain disorders , 2001, Behavioural Brain Research.

[104]  S. Hill,et al.  Sensitivity of histamine H3 receptor agonist-stimulated [35S]GTPγ[S]binding to pertussis toxin , 1996 .

[105]  J. Schwartz,et al.  Highly Potent Fluorescence‐Tagged Nonimidazole Histamine H3 Receptor Ligands , 2007, ChemMedChem.

[106]  H. H. Refsgaard,et al.  Cinnamic amides of (S)-2-(aminomethyl)pyrrolidines are potent H3 antagonists. , 2004, Bioorganic & medicinal chemistry.

[107]  Keyue Liu,et al.  Histaminergic Involvement in Neuropathic Pain Produced by Partial Ligation of the Sciatic Nerve in Rats , 2006, Regional Anesthesia & Pain Medicine.

[108]  P. Hooper.  Insulin Signaling, GSK-3, Heat Shock Proteins and the Natural History of Type 2 Diabetes Mellitus: A Hypothesis. , 2007, Metabolic syndrome and related disorders.

[109]  R. Faghih,et al.  Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor , 2006, Neuropharmacology.

[110]  J. Schwartz,et al.  New histamine H(3)-receptor ligands of the proxifan series: imoproxifan and other selective antagonists with high oral in vivo potency. , 2000, Journal of medicinal chemistry.

[111]  W. Nauta,et al.  Hypothalamic regulation of sleep in rats; an experimental study. , 1946 .

[112]  T. Vortherms,et al.  In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. , 2008, Bioorganic & medicinal chemistry letters.

[113]  Sandy J. Wilson,et al.  Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[114]  P. Leff.  Inverse agonism: theory and practice. , 1995, Trends in pharmacological sciences.

[115]  R. Raddatz,et al.  Chapter 4 Recent Advances in Drug Discovery of Histamine H3 Antagonists , 2007 .

[116]  F. Monsma,et al.  Cloning and characterization of a novel human histamine receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[117]  J. Schwartz,et al.  Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities. , 2003, Bioorganic & medicinal chemistry.

[118]  D. Roberts,et al.  The quantitative measurement of motor inco‐ordination in naive mice using an accelerating rotarod , 1968 .

[119]  M. Jackson,et al.  Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.

[120]  T. Ohkubo,et al.  Regulation of substance P release mediated via prejunctional histamine H3 receptors. , 1995, European journal of pharmacology.

[121]  H. Haas,et al.  The physiology of brain histamine , 2001, Progress in Neurobiology.

[122]  E. Bush,et al.  Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. , 2004, European journal of pharmacology.

[123]  R. Yoshimoto,et al.  Distinctive role of central histamine H3 receptor in various orexigenic pathways. , 2008, European journal of pharmacology.

[124]  Turning from monogamy to strategic promiscuity. , 2004, Drug discovery today.

[125]  M. Mor,et al.  Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series. , 2006, Bioorganic & medicinal chemistry.

[126]  H. Haas,et al.  Histamine excites GABAergic cells in the rat substantia nigra and ventral tegmental area in vitro , 2002, Neuroscience Letters.

[127]  A. Depaulis,et al.  Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy , 2002, Neuroscience.

[128]  Sandy J. Wilson,et al.  Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[129]  G. Abbott,et al.  Cardioprotective Effect of Histamine H3-Receptor Activation: Pivotal Role of Gβγ-Dependent Inhibition of Voltage-Operated Ca2+ Channels , 2008, Journal of Pharmacology and Experimental Therapeutics.

[130]  M. Berlin,et al.  Recent advances in the development of histamine H3 antagonists , 2007, Expert opinion on therapeutic patents.

[131]  T. Lovenberg,et al.  Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. , 2001, The Journal of pharmacology and experimental therapeutics.

[132]  Y. Masuho,et al.  Molecular Cloning and Characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes* , 2000, The Journal of Biological Chemistry.

[133]  P. Blandina,et al.  Acetylcholine, histamine, and cognition: two sides of the same coin. , 2004, Learning & memory.

[134]  A. Hancock,et al.  Structure-activity relationships of arylbenzofuran H3 receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[135]  C. Dvorak,et al.  A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. , 2003, Journal of medicinal chemistry.

[136]  Min Zhang,et al.  Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug–drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs , 2005, Brain Research.

[137]  Holger Stark,et al.  High constitutive activity of native H3 receptors regulates histamine neurons in brain , 2000, Nature.

[138]  J. Hey,et al.  Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. , 2003, Bioorganic & medicinal chemistry letters.

[139]  S. W. Ranson.  SOMNOLENCE CAUSED BY HYPOTHALAMIC LESIONS IN THE MONKEY , 1939 .

[140]  J. Schwartz,et al.  Histamine H3‐receptor‐mediated [35S]GTPγ[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors , 2002, British journal of pharmacology.

[141]  H. Stark,et al.  Azomethine prodrugs of (R)-alpha-methylhistamine, a highly potent and selective histamine H3-receptor agonist. , 2001, Current Medicinal Chemistry.

[142]  Dr Peter Norman.  A H3 antagonist for treating allergic rhinitis: a development candidate? , 2007 .

[143]  Emmanuel Mignot,et al.  The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[144]  Youssef L Bennani,et al.  Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[145]  Nicholas J. Carruthers,et al.  Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. , 2001, Molecular pharmacology.

[146]  H. Prast,et al.  Importance of histamine in modulatory processes, locomotion and memory , 2001, Behavioural Brain Research.

[147]  R. Yoshimoto,et al.  Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. , 2008, Journal of medicinal chemistry.

[148]  J. Szewczyk,et al.  An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism. , 2007, Chirality.

[149]  T. Lovenberg,et al.  Behavioral characterization of mice lacking histamine H(3) receptors. , 2002, Molecular pharmacology.

[150]  R. Leurs,et al.  Identification of rat H3 receptor isoforms with different brain expression and signaling properties. , 2001, Molecular pharmacology.

[151]  J. Schwartz,et al.  Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat , 1990, Brain Research.

[152]  J. Schwartz,et al.  [125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[153]  J. Shimada,et al.  Diamine derivatives containing imidazolidinylidene propanedinitrile as a new class of histamine H3 receptor antagonists. Part I. , 2008, Bioorganic & medicinal chemistry letters.

[154]  Scott D Bembenek,et al.  Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. , 2006, Journal of molecular graphics & modelling.

[155]  P. Tosco,et al.  Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives. , 2005, Bioorganic & medicinal chemistry.

[156]  C. M. Davenport,et al.  Cloning, expression, and pharmacological characterization of a novel human histamine receptor. , 2001, Molecular pharmacology.

[157]  Rob Leurs,et al.  Keynote review: histamine H3 receptor antagonists reach out for the clinic. , 2005, Drug discovery today.

[158]  P. McGuire,et al.  Functional neuroimaging in schizophrenia: diagnosis and drug discovery. , 2008, Trends in pharmacological sciences.

[159]  Rob Leurs,et al.  Evaluation of Histamine H1-, H2-, and H3-Receptor Ligands at the Human Histamine H4 Receptor: Identification of 4-Methylhistamine as the First Potent and Selective H4 Receptor Agonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[160]  M. Mor,et al.  Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold. , 2006, Bioorganic & medicinal chemistry letters.

[161]  H. Yoshimatsu,et al.  Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. , 2004, Diabetes.

[162]  Margaret Fahnestock,et al.  Kindling and status epilepticus models of epilepsy: rewiring the brain , 2004, Progress in Neurobiology.

[163]  Rob Leurs,et al.  Discovery of Naturally Occurring Splice Variants of the Rat Histamine H3 Receptor That Act as Dominant-Negative Isoforms , 2006, Molecular Pharmacology.

[164]  P. Tosco,et al.  Non-imidazole histamine NO-donor H3-antagonists. , 2005, Farmaco.

[165]  J. Schwartz,et al.  Influence of bulky substituents on histamine h(3) receptor agonist/antagonist properties. , 2002, Journal of medicinal chemistry.

[166]  G. Fox,et al.  Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. , 2006, Molecular interventions.

[167]  L. Danober,et al.  Pathophysiological mechanisms of genetic absence epilepsy in the rat , 1998, Progress in Neurobiology.

[168]  Holger Stark,et al.  Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. , 2002, Journal of medicinal chemistry.

[169]  Xiaohong Zhu,et al.  Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands. , 2008, Bioorganic & medicinal chemistry letters.

[170]  E. Mignot,et al.  Narcolepsy with cataplexy , 2007, The Lancet.

[171]  J. Schwartz,et al.  Histaminergic transmission in the mammalian brain. , 1991, Physiological reviews.

[172]  I. Chessell,et al.  Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain , 2008, PAIN.

[173]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[174]  A. Franchitto,et al.  H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway , 2007, Laboratory Investigation.

[175]  P. Chazot,et al.  Immunological identification of the mammalian H3 histamine receptor in the mouse brain , 2001, Neuroreport.

[176]  H. Yoshimatsu,et al.  Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. , 2001, Diabetes.

[177]  Wolfgang Sippl,et al.  Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists. , 2004, Mini reviews in medicinal chemistry.

[178]  M. Minzenberg,et al.  Modafinil: A Review of Neurochemical Actions and Effects on Cognition , 2008, Neuropsychopharmacology.

[179]  H. Stark,et al.  Model of a specific human histamine H3 receptor (hH3R) binding pocket suitable for virtual drug design , 2005, Inflammation Research.

[180]  F. Genre,et al.  Histamine regulates pancreatic carcinoma cell growth through H3 and H4 receptors , 2008, Inflammation Research.

[181]  A. Hancock,et al.  Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists. , 2004, Mini reviews in medicinal chemistry.

[182]  A. Hancock,et al.  Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. , 2003, Life sciences.

[183]  J. Arias-Montaño,et al.  Histamine H3‐receptor activation inhibits dopamine synthesis in rat striatum , 2000, Neuroreport.

[184]  H. Haas,et al.  Histamine excites noradrenergic neurons in locus coeruleus in rats , 2005, Neuropharmacology.

[185]  Sandy J. Wilson,et al.  Acute wake‐promoting actions of JNJ‐5207852, a novel, diamine‐based H3 antagonist , 2004 .

[186]  J. Schwartz,et al.  Fluorescent non-imidazole histamine H3 receptor ligands with nanomolar affinities. , 2006, Bioorganic & medicinal chemistry letters.

[187]  F. Rice,et al.  Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: Potential antinociceptive targets , 2007, Pain.

[188]  C. Papp-Jámbor,et al.  Cytochrom-P450-Enzyme und ihre Bedeutung für Medikamenteninteraktionen , 2002, Der Anaesthesist.

[189]  T. Keller,et al.  A practical view of 'druggability'. , 2006, Current opinion in chemical biology.

[190]  J. Arias-Montaño,et al.  Histamine H3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices , 2004, Neuroscience Letters.

[191]  J. Schwartz,et al.  Synthesis of Potent Non‐imidazole Histamine H3‐Receptor Antagonists , 1998, Archiv der Pharmazie.

[192]  J. Young,et al.  Histamine H3 receptor‐mediated inhibition of depolarization‐induced, dopamine D1 receptor‐dependent release of [3H]‐γ‐aminobutyric acid from rat striatal slices , 2001 .

[193]  H. Schaffhauser,et al.  Correlation between ex Vivo Receptor Occupancy and Wake-Promoting Activity of Selective H3 Receptor Antagonists , 2008, Journal of Pharmacology and Experimental Therapeutics.

[194]  R. Leurs,et al.  Clobenpropit (VUF-9153), a new histamine H3 receptor antagonist, inhibits electrically induced convulsions in mice. , 1994, European journal of pharmacology.

[195]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[196]  H. Kotani,et al.  Generation and Characterization of Highly Constitutive Active Histamine H3 Receptors , 2003, Journal of Pharmacology and Experimental Therapeutics.

[197]  C. Kamei.  Involvement of central histamine in amygdaloid kindled seizures in rats , 2001, Behavioural Brain Research.

[198]  H. Frey,et al.  Histamine in brain — its role in regulation of seizure susceptibility , 1991, Epilepsy Research.

[199]  H. Ohtsu,et al.  Anatomical, Physiological, and Pharmacological Characteristics of Histidine Decarboxylase Knock-Out Mice: Evidence for the Role of Brain Histamine in Behavioral and Sleep–Wake Control , 2002, The Journal of Neuroscience.

[200]  M. Karayiorgou,et al.  Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.

[201]  G. Gisselmann,et al.  Histamine Action on Vertebrate GABAA Receptors , 2008, Journal of Biological Chemistry.

[202]  G. Ait-Ghezala,et al.  Role of tau in Alzheimer's dementia and other neurodegenerative diseases , 2007 .

[203]  J. Baker.  Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells , 2008, BMC pharmacology.

[204]  A. Yamatodani,et al.  Comparison of the effect of an H3-inverse agonist on energy intake and hypothalamic histamine release in normal mice and leptin resistant mice with high fat diet-induced obesity , 2008, Behavioural Brain Research.

[205]  J. Schwartz,et al.  A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas , 1993, Neuroscience.

[206]  M. Nishibori,et al.  Phencyclidine and the dynamics of mouse brain histamine. , 1985, The Journal of pharmacology and experimental therapeutics.

[207]  J. Schwartz,et al.  The rat H3 receptor: gene organization and multiple isoforms. , 2001, Biochemical and biophysical research communications.

[208]  J. Tanaka,et al.  Distribution of the histaminergic neuron system in the central nervous system of rats; a fluorescent immunohistochemical analysis with histidine decar☐ylase as a marker , 1984, Brain Research.

[209]  K. Browman,et al.  Minimization of potential hERG liability in histamine H3 receptor antagonists , 2008, Inflammation Research.

[210]  W. Schunack,et al.  Epithelial cell proliferation is promoted by the histamine H(3) receptor agonist (R)-alpha-methylhistamine throughout the rat gastrointestinal tract. , 2006, European journal of pharmacology.

[211]  H. Stark,et al.  Refined Docking as a Valuable Tool for Lead Optimization: Application to Histamine H3 Receptor Antagonists , 2008, Archiv der Pharmazie.

[212]  J. Leysen,et al.  Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand. , 2006, Nuclear medicine and biology.

[213]  Michael A. Briggs,et al.  GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models , 2007, Journal of Pharmacology and Experimental Therapeutics.

[214]  K. Fink,et al.  Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors , 2005, Journal of Neural Transmission / General Section JNT.

[215]  L. Tuomisto,et al.  Histamine levels and clonic convulsions of electrically-induced seizure in mice: the effects of α-fluoromethylhistidine and metoprine , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.

[216]  J. Arrang,et al.  Constitutive activity of the histamine H3 receptor. , 2007, Trends in pharmacological sciences.

[217]  H. Haas,et al.  The role of histamine and the tuberomamillary nucleus in the nervous system , 2003, Nature Reviews Neuroscience.

[218]  A. Vasudevan,et al.  Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.

[219]  K. Cannon,et al.  Inhibition of chemical and low-intensity mechanical nociception by activation of histamine H3 receptors. , 2005, The journal of pain : official journal of the American Pain Society.

[220]  P. Bonaventure,et al.  Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[221]  J. A. Jablonowski,et al.  Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore. , 2007, Bioorganic & medicinal chemistry letters.

[222]  A. Yamatodani,et al.  Synthesis of novel 4(5)-(5-aminotetrahydropyran-2-yl)imidazole derivatives and their in vivo release of neuronal histamine measured by brain microdialysis. , 2007, Chemical & pharmaceutical bulletin.

[223]  P. Tosco,et al.  A new class of NO-donor H3-antagonists. , 2004, Farmaco.

[224]  A. Hancock,et al.  Detection of multiple H3 receptor affinity states utilizing [3H]A‐349821, a novel, selective, non‐imidazole histamine H3 receptor inverse agonist radioligand , 2006, British journal of pharmacology.

[225]  H. Stark,et al.  Improvement by FUB 181, a novel histamine H3-receptor antagonist, of learning and memory in the elevated plus-maze test in mice , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[226]  V. Santora,et al.  A new family of H3 receptor antagonists based on the natural product Conessine. , 2008, Bioorganic & medicinal chemistry letters.

[227]  W. Schunack,et al.  Novel histamine H3‐receptor antagonists and partial agonists with a non‐aminergic structure , 2001, British journal of pharmacology.

[228]  J. Brioni,et al.  A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands. , 2008, Assay and drug development technologies.

[229]  R. Leurs,et al.  Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function , 2008, Neuropharmacology.

[230]  Youssef L Bennani,et al.  4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration. , 2007, Bioorganic & medicinal chemistry letters.

[231]  S. L. Yates,et al.  Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists. , 1999, Journal of medicinal chemistry.

[232]  S. Hastrup,et al.  Antagonistic targeting of the histamine H3 receptor decreases caloric intake in higher mammalian species. , 2007, Biochemical pharmacology.

[233]  J. Schwartz,et al.  Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H(3)-receptor antagonists. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[234]  Jon T. Willie,et al.  Narcolepsy in orexin Knockout Mice Molecular Genetics of Sleep Regulation , 1999, Cell.

[235]  Thomas R. Miller,et al.  Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.

[236]  D. Macneil,et al.  Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus , 2006, Proceedings of the National Academy of Sciences.

[237]  J. Hobson,et al.  The effects of posterior hypothalamic lesions on behavioral and electrographic manifestations of sleep and waking in cats. , 1968, Archives italiennes de biologie.

[238]  J. Arrang,et al.  Autoregulation of McA-RH7777 Hepatoma Cell Proliferation by Histamine H3 Receptors , 2008, Journal of Pharmacology and Experimental Therapeutics.

[239]  Min Zhang,et al.  Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[240]  Kiev S. Ly,et al.  Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[241]  J. Arrang,et al.  Compared pharmacology of human histamine H3 and H4 receptors: structure–activity relationships of histamine derivatives , 2006, British journal of pharmacology.

[242]  G. Coruzzi,et al.  The Histamine H3 Receptor , 2000 .

[243]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[244]  R. Leurs,et al.  Molecular aspects of the histamine H3 receptor. , 2007, Biochemical pharmacology.

[245]  R. Egan,et al.  Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. , 1998, The Journal of pharmacology and experimental therapeutics.

[246]  Bryan L Roth,et al.  Molecular targets for treating cognitive dysfunction in schizophrenia. , 2007, Schizophrenia bulletin.